MedTrace Logo

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

NCT02974725 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 241

Last updated 2025-04-13

No results posted yet for this study

Summary

To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.

Conditions

Interventions

DRUG

LXH254

LXH254 will be supplied as tablet for oral use.

DRUG

LTT462

LTT462 will be supplied as hard gelatin capsule for oral use.

DRUG

Trametinib

Trametinib will be supplied as film-coated tablet for oral use

DRUG

Ribociclib

Ribociclib will be supplied in tablets and hard gelatin capsules.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-24
Primary Completion
2024-04-24
Completion
2024-04-24
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • France
  • Germany
  • Israel
  • Italy
  • Poland
  • South Korea
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02974725 on ClinicalTrials.gov